FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful... Read more.
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful... Read more.
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful... Read more.
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful... Read more.
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful... Read more.
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful... Read more.
Re: Shareholder Proposals to MIZUHO FINANCIAL GROUP, INC. (TOKYO:8411) and ORIENT CORPORATION (TOKYO:8585), and Launch of the Campaign Website
TOKYO–(BUSINESS WIRE)–Strategic Capital, Inc.: To Whom It May Concern Strategic Capital, Inc. (hereinafter referred to as “Strategic Capital”) is... Read more.
QAD | Redzone to Showcase AI-Powered Connected Workforce Platform at Hannover Messe 2026
HANNOVER, Germany–(BUSINESS WIRE)–QAD | Redzone, the company redefining manufacturing and supply chains through intelligent, adaptive solutions, announced... Read more.
QAD | Redzone Brings the Future of Agentic AI in Manufacturing to Hannover Messe 2026
The company will showcase how agentic AI is driving real-time execution so manufacturers can operate faster, adapt continuously and deliver measurable business outcomes.... Read more.
Accenture and Avanade Collaborate with Microsoft to Develop Agentic Factory to Help Reduce Manufacturing Downtime
New product introduced at Hannover Messe 2026 helps shop floor teams at manufacturers like Kruger Inc. and Nissha Metallizing Solutions address shop floor challenges... Read more.